TWI635864B - 寡核苷酸螯合複合物－多肽組合物及方法 - Google Patents

寡核苷酸螯合複合物－多肽組合物及方法 Download PDF

Info

Publication number
TWI635864B
TWI635864B TW102117594A TW102117594A TWI635864B TW I635864 B TWI635864 B TW I635864B TW 102117594 A TW102117594 A TW 102117594A TW 102117594 A TW102117594 A TW 102117594A TW I635864 B TWI635864 B TW I635864B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
chelate complex
rep
seq
pegylated
Prior art date
Application number
TW102117594A
Other languages
English (en)
Chinese (zh)
Other versions
TW201408308A (zh
Inventor
米歇爾 巴茲涅
安德魯 維隆
Original Assignee
雷普利可公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI635864(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 雷普利可公司 filed Critical 雷普利可公司
Publication of TW201408308A publication Critical patent/TW201408308A/zh
Application granted granted Critical
Publication of TWI635864B publication Critical patent/TWI635864B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
TW102117594A 2012-05-18 2013-05-17 寡核苷酸螯合複合物－多肽組合物及方法 TWI635864B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US61/648,711 2012-05-18
US201261695035P 2012-08-30 2012-08-30
US61/695,035 2012-08-30

Publications (2)

Publication Number Publication Date
TW201408308A TW201408308A (zh) 2014-03-01
TWI635864B true TWI635864B (zh) 2018-09-21

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102117594A TWI635864B (zh) 2012-05-18 2013-05-17 寡核苷酸螯合複合物－多肽組合物及方法

Country Status (34)

Country Link
US (1) US9492506B2 (https=)
EP (1) EP2849798B1 (https=)
JP (1) JP2015517504A (https=)
KR (1) KR102068109B1 (https=)
CN (1) CN104349793B (https=)
AU (1) AU2013262416B2 (https=)
BR (1) BR112014028654A2 (https=)
CA (1) CA2873529C (https=)
CL (1) CL2014003134A1 (https=)
CO (1) CO7131387A2 (https=)
CR (1) CR20140527A (https=)
CY (1) CY1124345T1 (https=)
DK (1) DK2849798T3 (https=)
DO (1) DOP2014000264A (https=)
EA (1) EA035967B1 (https=)
EC (1) ECSP14027694A (https=)
ES (1) ES2873844T3 (https=)
HR (1) HRP20210840T1 (https=)
HU (1) HUE054875T2 (https=)
IL (1) IL235548B (https=)
LT (1) LT2849798T (https=)
MX (1) MX346239B (https=)
MY (1) MY168778A (https=)
NZ (1) NZ703095A (https=)
PH (1) PH12014502551B1 (https=)
PL (1) PL2849798T3 (https=)
PT (1) PT2849798T (https=)
RS (1) RS62030B1 (https=)
SG (1) SG11201407599SA (https=)
SI (1) SI2849798T1 (https=)
SM (1) SMT202100319T1 (https=)
TW (1) TWI635864B (https=)
WO (1) WO2013170386A1 (https=)
ZA (1) ZA201408674B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723672C (en) 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
EP3511022A1 (en) 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
AU2013308045B2 (en) * 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042418A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2012021985A1 (en) * 2010-08-20 2012-02-23 Replicor Inc. Oligonucleotide chelate complexes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
EP2330194A3 (en) * 2002-09-13 2011-10-12 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
CA2543696A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
EP1942911A4 (en) * 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) * 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
KR20120095397A (ko) * 2009-10-16 2012-08-28 글락소 그룹 리미티드 Ｈｂｖ 안티센스 억제제
AU2013308045B2 (en) 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042418A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2012021985A1 (en) * 2010-08-20 2012-02-23 Replicor Inc. Oligonucleotide chelate complexes

Also Published As

Publication number Publication date
CA2873529C (en) 2020-08-18
IL235548A0 (en) 2015-01-29
HUE054875T2 (hu) 2021-10-28
US20130309201A1 (en) 2013-11-21
PT2849798T (pt) 2021-05-18
JP2015517504A (ja) 2015-06-22
WO2013170386A1 (en) 2013-11-21
MX2014014021A (es) 2015-02-10
KR102068109B1 (ko) 2020-01-21
PH12014502551A1 (en) 2015-01-21
EP2849798A1 (en) 2015-03-25
EP2849798A4 (en) 2016-03-09
AU2013262416A1 (en) 2014-12-18
BR112014028654A2 (pt) 2017-10-10
CA2873529A1 (en) 2013-11-21
CR20140527A (es) 2014-12-15
CY1124345T1 (el) 2022-07-22
EA201401278A1 (ru) 2015-04-30
ECSP14027694A (es) 2015-12-31
HK1204279A1 (en) 2015-11-13
KR20150013309A (ko) 2015-02-04
CN104349793B (zh) 2017-11-10
NZ703095A (en) 2016-07-29
TW201408308A (zh) 2014-03-01
PL2849798T3 (pl) 2021-10-18
IL235548B (en) 2019-07-31
ES2873844T3 (es) 2021-11-04
DK2849798T3 (da) 2021-05-31
CL2014003134A1 (es) 2015-02-13
EP2849798B1 (en) 2021-04-07
MY168778A (en) 2018-12-04
LT2849798T (lt) 2021-08-10
CN104349793A (zh) 2015-02-11
RS62030B1 (sr) 2021-07-30
DOP2014000264A (es) 2015-01-31
EA035967B1 (ru) 2020-09-07
HRP20210840T1 (hr) 2021-08-06
SG11201407599SA (en) 2014-12-30
MX346239B (es) 2017-03-13
US9492506B2 (en) 2016-11-15
ZA201408674B (en) 2016-01-27
SMT202100319T1 (it) 2021-09-14
CO7131387A2 (es) 2014-12-01
AU2013262416B2 (en) 2017-05-11
PH12014502551B1 (en) 2019-10-11
SI2849798T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
TWI635864B (zh) 寡核苷酸螯合複合物－多肽組合物及方法
US20230210887A1 (en) Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
EP3315608B1 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
TWI620568B (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
TWI881004B (zh) 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合
TWI648288B (zh) 寡核苷酸螯合複合物之調配物、用途及方法
CA3078960A1 (en) Methods for treating hepatitis b infection
JP2022521155A (ja) Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
CN116194120A (zh) 乙型肝炎患者的寡核苷酸治疗
US20250263705A2 (en) Pharmaceutical combinations for treatment of hbv
TW202140789A (zh) 靶向ｐｄ—ｌ１之方法及組合物
JP2024541559A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）タンパク質の発現を阻害するための組成物および方法
WO2025242158A1 (en) Combination treatments
HK1204279B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
RU2780021C2 (ru) Способы лечения инфекции гепатита в
HK40106696A (zh) 治疗乙型肝炎感染的方法
HK40091305A (zh) 乙型肝炎患者的寡核苷酸治疗
WO2025232886A1 (zh) 一种抑制乙型肝炎病毒的寡核苷酸、缀合物、组合物及其用途
HK40032229B (zh) 治疗乙型肝炎感染的方法
HK40032229A (en) Methods for treating hepatitis b infection

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees